The notion that metformin suppresses cancer growth through pathways other than insulin/IGF-1-dependent, indirect drug action has recently been supported by experiments in liver IGF-1-deficient (LID) mice, which had naturally decreased lung tumor multiplicity and burden compared with wild-type mice [28, 29]. The gene discussed is IGF1; the disease is cancer.